We would like to thank Drs. Aguilera and Sousa for their thoughtful commentary on our recent publication “Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis.” In particular, we would like to thank the authors for calling their important work to our attention.
Their identification of Glutathione S-transferase T1 (GSTT1) gene mismatch between donor and recipient, specifically Donor (−)/Recipient (+), as a potential predictor for developing plasma cell-rich rejection (PCR) was a critical breakthrough in this field. Additionally, their work also suggests that serologic evaluation of anti-GSTT1 antibodies may be a useful marker in PCR diagnosis and disease response to corticosteroid therapy (1). It is satisfying that the findings from our histopathologic assessment of post-transplant plasma cell hepatitis correlates with their observations (2).
As the authors’ mentioned, the findings of our study and their prior work may be of particular clinical relevance in the evaluation of patients for whom a pre-liver transplantation (LT) diagnosis was not established (i.e., those in fulminant liver failure of unknown etiology). The current diagnostic algorithm does not provide adequate guidance with unclear pre-LT diagnosis, reflecting the fact that it is entirely clinical context-based, but not immuno-pathobiology-based diagnosis (3). Accordingly, the roles of Immunoglobulin subclass 4 (IgG4) immunostaining and serologic antibody testing are not well-established in differentiating PCR from recurrent autoimmune hepatitis (rAIH). This is despite prior literature demonstrating that PCR is not a immunologically homogenous entity by its current definition (4).
Consequently, our studies suggest a potential complementary approach to the evaluation of these individuals. One possible diagnostic algorithm could be evaluating the IgG4 Positivity by immunohistochemistry in combination with anti-GSTT1 antibody serologic testing. Based on the findings of our studies, high IgG4 Positivity and elevated anti-GSTT1 antibodies would be highly suggestive of PCR. Conversely, low IgG4 Positivity and absent anti-GSTT1 antibodies may be confer a diagnosis of rAIH. A study in which IgG4 Positivity and anti-GSTT1 antibodies are identified in the same subjects is warranted. Additionally, as our works only evaluated a combined 28 cases of PCR and rAIH, further studies with a larger cohort are needed (1, 2).
Author Contributions
BH participated in the conception and draft of the manuscript. JK participated in the composition of the manuscript. TS participated in generating the intellectual content and writing of the manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
IgG4, immunoglobulin subclass 4; GSTT1, Glutathione S-transferase T1; LT, liver transplantation; PCR, plasma cell-rich rejection; rAIH, recurrent autoimmune hepatitis.
References
- 1. Aguilera I, Sousa JM, Gavilán F, Bernardos A, Wichmann I, Nuñez-Roldán A. Glutathione S-Transferase T1 Mismatch Constitutes a Risk Factor Forde Novoimmune Hepatitis after Liver Transplantation. Liver Transpl (2004) 10(9):1166–72. 10.1002/lt.20209 [DOI] [PubMed] [Google Scholar]
- 2. Horwich BH, Liang TZ, Dodge JL, Chopra S, Kahn JA, Saito T. Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis. Transpl Int (2022) 35:10182. 10.3389/ti.2022.10182 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Demetris AJ, Bellamy C, Hübscher SG, O'Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transpl (2016) 16(10):2816–35. 10.1111/ajt.13909 [DOI] [PubMed] [Google Scholar]
- 4. Castillo-Rama M, Sebagh M, Sasatomi E, Randhawa P, Isse K, Salgarkar AD, et al. "Plasma Cell Hepatitis" in Liver Allografts: Identification and Characterization of an IgG4-Rich Cohort. Am J Transplant (2013) 13(11):2966–77. 10.1111/ajt.12413 [DOI] [PubMed] [Google Scholar]
